Effect of Self-administered tDCS in Patients With MDD

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

May 2, 2019

Study Completion Date

May 2, 2019

Conditions
Major Depressive Disorder
Interventions
DEVICE

tDCS treatment

Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).

DRUG

Antidepressant Drug(escitalopram)

Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.

Trial Locations (1)

06591

Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul

All Listed Sponsors
collaborator

Ybrain Inc.

INDUSTRY

lead

Jeong-Ho Chae

OTHER

NCT04543123 - Effect of Self-administered tDCS in Patients With MDD | Biotech Hunter | Biotech Hunter